Akari Therapeutics (AKTX) Return on Equity (2015 - 2026)

Akari Therapeutics has disclosed Return on Equity across 12 years of filings, most recently posting 0.01% for Q1 2026.

• Return on Equity for Q1 2026 came in at 0.01%, down 1.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (down 1.0% YoY), and the FY2025 annual result was 0.01%, up 1.0% from the prior year.
• Return on Equity came in at 0.01% for Q1 2026 at Akari Therapeutics, down from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 20.9% in Q4 2023 to a low of 0.08% in Q3 2023.
• The 5-year median for Return on Equity is 0.01% (2025), against an average of 1.49%.
• Across the five-year window, Return on Equity jumped 2092 bps in 2023 and tumbled 2093 bps in 2024, its largest moves.
• Akari Therapeutics' Return on Equity stood at 0.02% in 2022, then soared by 107777 bps to 20.9% in 2023, then plunged by 100 bps to 0.03% in 2024, then soared by 72 bps to 0.01% in 2025, then sank by 89 bps to 0.01% in 2026.
• The last three Return on Equity figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.